GOVXW Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 May 2024 @ 09:30):

Stats
Today's Volume	3 717.00
Average Volume	0.00
Market Cap	5.49M
EPS	$-0.317 ( 2023-09-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00400 (4.84%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-22	Mckee Kelly T. Jr.	Buy	6 944	Common Stock
2023-09-25	Mckee Kelly T. Jr.	Buy	9 653	Common Stock
2023-08-25	Dodd David A	Buy	35 087	Common Stock
2023-08-18	Reynolds Mark	Buy	10 000	Common Stock
2023-08-01	Spencer John N Jr	Buy	50 000	Stock Option

INSIDER POWER
99.80
Last 95 transactions
Buy: 15 412 165 \| Sell: 50 000

GeoVax Labs, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GeoVax Labs, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-74 169.00 (0.00 %)
EPS:	$-14.29

FY	2023
Revenue:	$0
Gross Profit:	$-74 169.00 (0.00 %)
EPS:	$-14.29

FY	2022
Revenue:	$81 000.00
Gross Profit:	$24 716.00 (30.51 %)
EPS:	$-12.39

FY	2021
Revenue:	$385 501
Gross Profit:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

GeoVax Labs, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

GeoVax Labs, Inc.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.